Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Starts & Stops compiles all the clinical trial announcements, initiations, completions and suspensions tracked by Meddevicetracker. This edition covers trial announcements from Nov. 5 through Nov. 11, including trial announcements from Medtronic, Evaheart, and VentureMed.
Latest From Innovation
A snapshot of medical device approvals captured in Medtech Insight's Approvals Tracker. A muscle stimulation device to treat urinary incontinence passed US FDA's review, while a peripheral artery stent with a new delivery system gained European sign off.
Market Intel: Apps for Epilepsy, Steps for Health, Meditation Guides, Mouth Labs Cross Digital Divide For Better Health
Startups at the convergence of technology and biomedical innovations showcased compelling innovations at this week's Exponential Medicine conference in San Diego. This article offers a roundup of new devices targeting a wide range of applications from neurology, cardiology, chronic diseases and wellness.
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Nov. 3 - Nov. 9, includes trial data presented at the VIVA (Vascular InterVentional Advances) conference in Las Vegas, Nov. 5-8 as well as data from the initial experience with Medtronic's 34-mm CoreValve Evolut R TAVR system and the PARTNER IIA trial of Edwards' Sapien XT TAVR system.
When ALung Technologies was selected in 2015 by US FDA to participate in the agency's Expedited Access Pathway program for its novel Hemolung device, the firm wasn't necessarily sure what it was getting itself into. See what ALung CEO Pete DeComo said about the pathway – now called the Breakthrough Devices Program – here.
A snapshot of global medical device approvals captured during the past week in Medtech Insight's Approvals Tracker. Two devices to help surgeons performing thyroid surgery made the list, as did several devices in the diabetes space.
Pacts In Medtech: Myriad/Pfizer Deal Headlines Oncology-Heavy List Of Deals In September And October
Derived from Strategic Transactions, Informa's premium source for tracking life-sciences deals, the bimonthly Pacts In Medtech feature highlights notable technology alliances, R&D partnerships and commercial collaborations. This edition covers industry pacts that were sealed in September and October 2018.
Results Recap: Bluegrass Vascular's Novel Inside-Out Access Catheter For TCVO Succeeds In Early Cases
Results Recap is Medtech Insight's exclusive summary of clinical trial results that have been announced or published in the past week, based on information collected by Meddevicetracker. This week's edition, covering the week of Oct. 26 - Nov. 2, includes an announcement of the top-line results from 37 cases with Blue Grass Vascular Technologies' Surfacer Inside-Out Access Catheter System.
With 25 device and diagnostics start-ups in its portfolio, the Pittsburgh Life Sciences Greenhouse aims to establish life-sciences companies in Western Pennsylvania by leveraging the area's top schools and best-in-class medical facilities. See what the Greenhouse's Harold Safferstein said about it here.
Devices that collect and communicate patient data present opportunities for device-makers to have a closer relationship with end-users, but most device companies have little experience working directly with patients. Device firms need to close this gap by seeing the patients who use their devices as their primary customers, rather than just focusing on intermediaries like doctors, hospitals, and payers, industry experts tell Medtech Insight.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.